Traders should prepare for the earnings call on March 17 for potential updates on ZEVASKYN commercial performance, manufacturing capacity, and financial runway. Absence of data suggests this release is logistical, not substantive.
Price Chart
Executive Summary
Abeona Therapeutics announced it will discuss its fourth quarter and full year 2025 financial results on March 17, 2026, but did not release any actual financial data in this press release. The company highlighted its commercial-stage status with ZEVASKYN® and upcoming participation in the Leerink Global Healthcare Conference.
Key Facts
- Abeona Therapeutics will host an earnings call on March 17, 2026, to discuss Q4 and full year 2025 financial results.
- No financial results were disclosed in this press release.
- The company is commercializing ZEVASKYN®, an autologous cell-based gene therapy for RDEB.
- Management will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026.
- Forward-looking statements emphasize risks related to commercialization, manufacturing, regulatory approvals, and patient enrollment.
Financial Impact
No financial data released — impact cannot be quantified at this time
Risk Factors
- Risk that ZEVASKYN fails to gain market traction or that manufacturing cannot scale to meet demand.
- Regulatory risk related to FDA inspections of the cGMP manufacturing facility.
- Clinical trial enrollment challenges could delay development programs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248223 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $5.47 $5.57 | ▲ +1.83% | ▲ +1.01% | $5.03 (−8.14%) |
Aug 14, 2026 6w ago | Institutional Cluster | $5.94 $6.06 | ▲ +2.02% | ▲ +3.21% | $5.03 (−15.40%) |
Aug 13, 2026 7w ago | 8-K | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Aug 13, 2026 7w ago | Press Release | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Jul 9, 2026 12w ago | Insider Cluster | $6.98 $7.02 | ▲ +0.57% | ▲ +1.13% | $5.03 (−28.01%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▲ +1.24% | ▲ +3.47% | $5.03 (−11.06%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▼ −1.24% | ▼ −3.47% | $5.03 (+11.06%) |
Jun 12, 2026 16w ago | 8-K | $5.53 $5.77 | ▲ +4.34% | ▲ +3.67% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | 8-K | $5.53 $5.65 | ▲ +2.17% | ▲ +1.74% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | Insider Cluster | $5.36 $5.65 | ▼ −5.41% | ▼ −1.98% | $5.03 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access